Almirall and Novo Nordisk Join Forces for the Development of NN-8828 to Treat Dermatological Diseases
Shots:
- Almirall and Novo Nordisk have signed an exclusive license agreement for rights to NN-8828, the IL-21 targeting monoclonal antibody
- As per the agreement, Novo Nordisk is entitled for an upfront payment along with additional milestones on achieving development and commercialization plus tiered sales-based royalties while Almirall gains global development and commercialization rights to the drug for inflammatory & autoimmune skin diseases
- NN-8828, developed by Novo Nordisk till P-II for non-dermatological disease, aims at targeting cytokine IL-21 to inhibit the downstream signaling pathways, blocking the pathophysiological functions induced by it in various immune cells
Ref: Businesswire | Image: Almirall
Related News:- Almirall Received EC’s Approval for Ebglyss (lebrikizumab) to Treat Moderate-to-severe Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
